Epstein-Barr Virus and the Pathogenesis of Diffuse Large B-Cell Lymphoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F23%3A73623495" target="_blank" >RIV/61989592:15110/23:73623495 - isvavai.cz</a>
Alternative codes found
RIV/00098892:_____/23:10157998
Result on the web
<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967091/" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967091/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/life13020521" target="_blank" >10.3390/life13020521</a>
Alternative languages
Result language
angličtina
Original language name
Epstein-Barr Virus and the Pathogenesis of Diffuse Large B-Cell Lymphoma
Original language description
Epstein-Barr virus (EBV), defined as a group I carcinogen by the World Health Organization (WHO), is present in the tumour cells of patients with different forms of B-cell lymphoma, including Burkitt lymphoma, Hodgkin lymphoma, post-transplant lymphoproliferative disorders, and, most recently, diffuse large B-cell lymphoma (DLBCL). Understanding how EBV contributes to the development of these different types of B-cell lymphoma has not only provided fundamental insights into the underlying mechanisms of viral oncogenesis, but has also highlighted potential new therapeutic opportunities. In this review, we describe the effects of EBV infection in normal B-cells and we address the germinal centre model of infection and how this can lead to lymphoma in some instances. We then explore the recent reclassification of EBV+ DLBCL as an established entity in the WHO fifth edition and ICC 2022 classifications, emphasising the unique nature of this entity. To that end, we also explore the unique genetic background of this entity and briefly discuss the potential role of the tumour microenvironment in lymphomagenesis and disease progression. Despite the recent progress in elucidating the mechanisms of this malignancy, much work remains to be done to improve patient stratification, treatment strategies, and outcomes.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30109 - Pathology
Result continuities
Project
<a href="/en/project/EF16_019%2F0000868" target="_blank" >EF16_019/0000868: Molecular, cellular and clinical approach to healthy ageing</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Life
ISSN
2075-1729
e-ISSN
2075-1729
Volume of the periodical
13
Issue of the periodical within the volume
2
Country of publishing house
CH - SWITZERLAND
Number of pages
18
Pages from-to
521
UT code for WoS article
000941401400001
EID of the result in the Scopus database
2-s2.0-85148862694